Abstract
Estrogens have been recently postulated as potential agents in the development and progression of prostate cancer. Previous studies have demonstrated presence of both variants of estrogen receptor (ER); ER alpha (ERα) and ER beta (ERβ) in differing proportions between normal prostate and prostate cancer. It has been previously suggested that estrogens may either accelerate or inhibit growth of prostate cancer cell growth, depending on ER status. In particular, ERβ is considered to have a growth inhibitory role in prostate tissue. ERβ is significantly expressed in human prostate cancer cells, and hence it is considered a key factor for anti-cancer therapy. Therefore, various types of ERβ ligands have been investigated to clarify the mechanism of ERβ-mediated pathway of inhibitory effects on prostate cancer cells. Herein, we review recent examinations of ERs in prostate cancer, and the significance of ER mediated signaling pathways, with a focus on ERβ, as prospective therapeutic targets in prostate cancer.
Keywords: Estrogen receptor alpha(ERα), estrogen receptor beta (ERβ), GRP30, prostate cancer, steroid metabolism
Current Molecular Pharmacology
Title:Estrogen Receptor Expression and its Relevant Signaling Pathway in Prostate Cancer: A Target of Therapy
Volume: 5
Author(s): Yasuhiro Nakamura, Keely M McNamara and Hironobu Sasano
Affiliation:
Keywords: Estrogen receptor alpha(ERα), estrogen receptor beta (ERβ), GRP30, prostate cancer, steroid metabolism
Abstract: Estrogens have been recently postulated as potential agents in the development and progression of prostate cancer. Previous studies have demonstrated presence of both variants of estrogen receptor (ER); ER alpha (ERα) and ER beta (ERβ) in differing proportions between normal prostate and prostate cancer. It has been previously suggested that estrogens may either accelerate or inhibit growth of prostate cancer cell growth, depending on ER status. In particular, ERβ is considered to have a growth inhibitory role in prostate tissue. ERβ is significantly expressed in human prostate cancer cells, and hence it is considered a key factor for anti-cancer therapy. Therefore, various types of ERβ ligands have been investigated to clarify the mechanism of ERβ-mediated pathway of inhibitory effects on prostate cancer cells. Herein, we review recent examinations of ERs in prostate cancer, and the significance of ER mediated signaling pathways, with a focus on ERβ, as prospective therapeutic targets in prostate cancer.
Export Options
About this article
Cite this article as:
Nakamura Yasuhiro, M McNamara Keely and Sasano Hironobu, Estrogen Receptor Expression and its Relevant Signaling Pathway in Prostate Cancer: A Target of Therapy, Current Molecular Pharmacology 2012; 5 (3) . https://dx.doi.org/10.2174/1874467211205030008
DOI https://dx.doi.org/10.2174/1874467211205030008 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Modulation of Expression and Activity of ABC Transporters by the Phytoestrogen Genistein. Impact on Drug Disposition
Current Medicinal Chemistry Activation of Sphingosine Kinase-1 in Cancer: Implications for Therapeutic Targeting
Current Molecular Pharmacology Natural Compounds A Weapon to Ameliorate Breast Cancer Cells: A Review
Anti-Cancer Agents in Medicinal Chemistry Cognitive Function and Quality of Life in Mild Thyroid Hormone Deficiency
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Targeting Apoptosis to Treat Multiple Sclerosis
Current Drug Discovery Technologies Aldehyde Dehydrogenase as a Marker for Stem Cells
Current Stem Cell Research & Therapy Phosphodiesterase 5 Inhibitors - Drug Design and Differentiation Based on Selectivity, Pharmacokinetic and Efficacy Profiles
Current Pharmaceutical Design Nanoparticle-Delivered Quercetin for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member
Current Cancer Therapy Reviews Adenosine Monophosphate-activated Protein Kinase (AMPK) Activators For the Prevention, Treatment and Potential Reversal of Pathological Pain
Current Drug Targets Neuroglobin and Estrogen Receptors: A New Pathway of Cell Survival and Cell Death Balance
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Delivery of Therapeutics and Molecules Using Self-Assembled Peptides
Current Medicinal Chemistry Nanoemulsions for Improved Efficacy of Phytotherapeutics- A Patent Perspective
Recent Patents on Nanotechnology Targeting IAPs as An Approach to Anti-Cancer Therapy
Current Topics in Medicinal Chemistry Therapeutic Potential of Perineural Invasion, Hypoxia and Desmoplasia in Pancreatic Cancer
Current Pharmaceutical Design Polymeric Systems as Nanodevices for siRNA Delivery
Current Gene Therapy Bioinformatics Analysis of Chicken miRNAs Associated with Monocyte to Macrophage Differentiation and Subsequent IFNγ Stimulated Activation
MicroRNA Nitric Oxide, Epileptic Seizures, and Action of Antiepileptic Drugs
CNS & Neurological Disorders - Drug Targets Toxicity Burden in Head and Neck Cancer: Past, Present, and Future Strategies
Current Cancer Therapy Reviews New Approaches for the Synthesis of Fused Thiophene, Pyrazole, Pyran and Pyridine Derivatives with Anti-Proliferative Together with c-Met Kinase and Prostate Cancer Cell Inhibitions
Anti-Cancer Agents in Medicinal Chemistry